![]() |
|
|
Vol. 290, Issue 3, 1417-1426, September 1999
Department of Physiology and Biophysics, Dalhousie
University, Halifax, Nova Scotia, Canada (L.M.S., S.E.J., T.O.,
T.F.M.); Nihon University School of Medicine, 2nd Department of
Internal Medicine, Itabashi-ku, Tokyo, Japan (Y.K.); and Sepracor Inc.,
Marlborough, Massachusetts (J.R.M.)
Terodiline was widely prescribed for urinary incontinence before
reports of adverse cardiac effects that included bradycardia, QT
lengthening, and ventricular tachyarrhythmia. The present study on
guinea pig papillary muscles and ventricular myocytes was undertaken to
gain insight into the cardioactive properties of the drug. Clinically
relevant concentrations (<10 µM) of terodiline lengthened the action
potential duration by up to 12%; higher concentrations shortened the
duration in a concentration-dependent manner. The drug depressed
maximal upstroke velocity in a use-dependent manner; the
IC50 value was near 150 µM in muscles driven at 1 Hz, 60 µM at 3 Hz, 38 µM at 5 Hz, and 3 µM at 1 Hz in muscles
depolarized with 14 mM K+. Submicromolar terodiline
frequently had a small positive inotropic effect, whereas micromolar
concentrations depressed force in a frequency-dependent manner.
Voltage-clamp results on myocytes indicate that terodiline inhibits
three membrane currents that govern repolarization: 1) E4031-sensitive,
rapidly activating K+ current with an IC50
value near 0.7 µM as previously reported; 2) slowly activating,
delayed-rectifier K+ current with an IC50 value
of 26 µM; and 3) L-type Ca2+ current with an
IC50 value of 12 µM. These findings are correlated with
the changes in action potential configuration and developed tension and
discussed in relation to the cardiotoxic effects of the drug.
This article has been cited by other articles:
![]() |
C.-E. Chiang, H.-N. Luk, T.-M. Wang, and P. Y.-A. Ding Prolongation of cardiac repolarization by arsenic trioxide Blood, August 28, 2002; 100(6): 2249 - 2252. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Carlsson Drug-induced torsade de pointes: the perspectives of industry Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K114 - K120. [Abstract] [PDF] |
||||